Arctic Bioscience

Arctic Bioscience - Minutes of the Extraordinary General Meeting

An Extraordinary General Meeting in Arctic Bioscience AS was held Tuesday 11

November 2025 at 10:00 (CET). All the items on the agenda were addressed and

approved. Attached is the minutes of the Extraordinary General Meeting.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Phone: +47 920 84 601

Jone R. Slinning

CFO

Mobile: +47 948 75 469

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI Terminal